ความเชื่อมั่นในอุตสาหกรรมชีวเภสัชภัณฑ์พุ่งสูงสุดในรอบสี่ปี แม้เผชิญแรงต้านด้านภูมิรัฐศาสตร์

GSK's $10.6 billion acquisition of Nuvalent is a major M&A deal that signals GSK's strategic growth.

Eli Lilly's acquisition of 10 companies this year, led by a $7.8 billion deal for Centessa, signals aggressive M&A strategy and industry confidence.

GSK's $10.6 billion acquisition of Nuvalent is a major M&A event that validates Nuvalent's value.

Parabilis set a new biotech IPO record with a $670 million Nasdaq listing, indicating strong investor demand.

Eli Lilly's $7.8 billion acquisition of Centessa is a major M&A event that validates Centessa's value.

Sun Pharma's $11.75 billion takeover of Organon is a significant M&A deal that boosts Organon's valuation.